Washington Trust Advisors’s Moderna MRNA Stock Holding History

Washington Trust Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$914	Buy	+18	New	+$840	﹤0.01%	662
2025 Q3	–	Sell	-35	Closed	-$966	–	707
2025 Q2	$966	Hold	35	–	–	﹤0.01%	625
2025 Q1	$992	Hold	35	–	–	﹤0.01%	629
2024 Q4	$1.46K	Hold	35	–	–	﹤0.01%	631
2024 Q3	$2.34K	Hold	35	–	–	﹤0.01%	629
2024 Q2	$4.16K	Hold	35	–	–	﹤0.01%	585
2024 Q1	$3.73K	Hold	35	–	–	﹤0.01%	600
2023 Q4	$3.48K	Hold	35	–	–	﹤0.01%	610
2023 Q3	$3.62K	Hold	35	–	–	﹤0.01%	587
2023 Q2	$4.25K	Hold	35	–	–	﹤0.01%	567
2023 Q1	$5.38K	Hold	35	–	–	﹤0.01%	592
2022 Q4	$6.29K	Hold	35	–	–	﹤0.01%	567
2022 Q3	$4K	Hold	35	–	–	﹤0.01%	757
2022 Q2	$5K	Hold	35	–	–	﹤0.01%	749
2022 Q1	$6K	Hold	35	–	–	﹤0.01%	790
2021 Q4	$9K	Buy	+35	New	+$10.2K	﹤0.01%	749

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Washington Trust Advisors's MRNA Position: Q1 2026 in Review

Washington Trust Advisors opened a new position in Moderna (MRNA) in Q1 2026: 18 shares worth $914. The stake represents ﹤0.01% of the portfolio and ranks #662 among its holdings. This is a return to the name: Washington Trust Advisors previously reported a position in MRNA as recently as Q2 2025.

Washington Trust Advisors first reported a position in MRNA in Q4 2021 and has held it in 16 quarters since. The position peaked at $9K in Q4 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

Washington Trust Advisors held 18 shares of Moderna worth $914 as of Q1 2026.
Moderna was a new Washington Trust Advisors position in Q1 2026.
Moderna made up ﹤0.01% of Washington Trust Advisors's portfolio in Q1 2026, its #662 holding.
Washington Trust Advisors first reported a position in Moderna in Q4 2021 and has held it in 16 quarters since.
Washington Trust Advisors's Moderna position peaked at $9K in Q4 2021.
722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Washington Trust Advisors's 13F filing for Q1 2026, filed 6 Apr 2026.